Pharmacotherapy Rounds

Pharmacotherapy rounds are designed for pharmacy residents and fellows, residency and fellowship preceptors, faculty, and practicing pharmacists. Activities are offered free of charge to all participants.

Schedule:

• Schedule 2012 - 2013

CE Flyers:

• Antipsychotics for the Treatment of Delirium in the Non-ICU Patient 0025-0000-L3-042-L01-P  05/23/2013
• Interprofessional Team-Based Care:  Is the Effort Worth the Reward  0025-0000-13-024-LO4-P  04/24/2013
• Keep Calm and Carry On: Antipsychotic Use for Behavioral Symptoms of Dementia  0025-0000-13-023-LO1-P  04/17/2013
• Let's Settle the Score:  CHADS2 vs CHA2DS2-VASc  0025-0000-13-022-LO1-P  04/10/2013
• Therapeutic Approaches for the Treatment of Lupus Nephritis  0025-000-13-020-L01-P  04/03/13
• Management of Bleeding in Patients Receiving New Oral Anticoagulants  0025-0000-13-019-L01-P  03/28/13
• Survive the Flu: Understanding the Virus, Vaccine, and Treatment 0025-0000-13-021-L01-P 03/21/13
• An Easy Pill to Swallow?  Tofacitinib, a Novel Oral Agent for the Treatment of Rheumatoid Arthritis  0025-0000-13-017-L01-P   03/14/13
• Macular Degeneration:  A Straight-Forward Look at Pharmacotherapy  0025-0000-13-012-L01-P  03/07/13
• Weighing the Options:  Lorcaserin and Phenteramine/Topiramate - Two New Options for Obesity Treatment  0025-0000-13-013-L01-P  02/27/13
• Dexmedetomidine:  Updating its Role in Sedation of Mechanically Ventilated Patients  0025-0000-13-002-L01-P  02/20/13
• Is it Worth the Switch?  Opioid Rotation in Cancer Pain  0025-0000-13-001-L01-P  02/13/13
• Bath Salts: Not for Human Consumption  0025-0000-12-346-L04-P  02/06/13
• When counting Sheep No Longer Works 0025-0000-12-345-L01-P  01/24/13
• How Low Can You Go?  Defining the Optimal Hemoglobin A1c level for Older Adults 0025-000-12-343-L01-P 01-31-13
• Suicide Rates in Children and Adolescents With Antidepressants  0025-000-12-341-LO1-P  01/17/13
• Discontinuation of Medications When They are No Longer Required 0025-0000-12-340-L04-P 01/10/13
• Sticks, Stones, Cancer and Bones 0025-000-12-338-L01-P  01/03/13
• The Role of Fidaxomicin in the Treatment of Clostridium Difficle Associated Diarrhea 0025-0000-12-339-L01-P  12/19/12
• TZDs: Why Are We Still Using These? Evaluation of the Risks and Benefits of TZDs in Treatment of Type II Diabetes Mellitus 0025-000-12-336 12/12/12
• Calcium Supplements:  Too Much of a Good Thing? 0025-0000-12-324-L01-P  11/29/12
• Opening the Gate with Ivacaftor, A New Therapy for Cystic Fibrosis 0025-0000-12-322-L01-P  11/15/12
• Unbreak My Heart":  Depression and Cariovascular Disease 0025-0000-12-311-L01-P  11/08/12
• Desensitization Protocols for Highly Sensitized Transplant Patients  0025-0000-12-328-L01-P 10/31/12
• Significant HAART-Antineoplastic Interactions 0025-0000-12-323-L02-P  10/24/12
• From HAART to PreEP:  The Role of Emtricitabine + Tenofovir (Truvada) for HIV Prevention 0025-0000-12-308-L02-P  10/17/12
• Bang for Your Buck Realizing a Role for the Pharmacist in Readmission Prevention  0025-0000-12-307-L04-P  10/10/12
• Managing Hypertension in the Elderly: Which Goal is the Best Goal? 0025-0000-12-261-L01-P 10/03/12
• Rivaroxaban for the Treatment of Acute Venous Thronboembolism   0025-0000-12-260-L04-P 09/27/12
• Home is Where the Heart is:  Pharmacists' role in the Patient-Centered Medical Home (PCMH) 0025-0000-12-310-L04-P 09/20/12
• Rationale Opioid Therapy for Cancer Pain    0025-0000-12-306-L01-P 09/13/12
• Status Update: Lacosamide for the Treatment of Status Epilepticus 0025-0000-12-244-L04-P 09/06/12
• Avengers Assemble! Accountable Care Organizations: Superhero Team or Time Bomb?0025-0000-12-245-L03-P 08/29/12
• Fluoroquinolone Use in Pediatric Patients   0025-0000-12-238-L04-P 08/22/12

Forms:

• Attendance Log Template
• Pharmacotherapy Rounds Application
• Guidelines
• Speaker Guidance
• Keywords for Pharmacotherapy Rounds Application

Deadlines:

• Topics for Pharmacotherapy Rounds must be submitted 10 weeks prior to presentation.
• Pharmacotherapy Rounds Application (CV, learning objectives and presentation outline etc.) must be submitted 45 business days prior to presentation.

PLEASE NOTE: Residents and fellows may not duplicate topics presented in the last two years.

Frequently Asked Questions:

Who should attend?
Pharmacy residents and fellows, residency and fellowship preceptors, faculty, and practicing pharmacists. This program is offered free of charge to participants and is supported only by the University of Maryland School of Pharmacy.

How is CE credit awarded?
Register on the sign-in sheet and complete online evaluation form in order to receive your continuing education statement of credit by mail.

How much credit is awarded?
One CE Credit Contact Hour (0.1 CEUs).

Relevant Links:

• Hopkins Past Presentation Topics 2011-2012
• University of Maryland Past Presentation Topics 2011-2012
• University of Maryland Past Presentation Topics 2012-2013

For More Information:

Contact the Continuing Education Office at 410-706-0761.

The University of Maryland School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmaceutical education.  These programs (UAN listed above) meet the ACPE criteria for 1.0 Contact Hour (0.1 CEU).  Statements of credit will be mailed within three weeks of each program to participants who successfully complete the program.  Successful completion of the program requires your signature on the completed evaluation form and on the session sign in sheet and participation at the entire program for which you are seeking credit.  Evaluation forms must be completed and returned at the conclusion of the program.  This program is supported solely by the University of Maryland School of Pharmacy.

The Johns Hopkins Hospital Department of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.